HK1208219A1 - -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽 - Google Patents

-{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽

Info

Publication number
HK1208219A1
HK1208219A1 HK15108828.4A HK15108828A HK1208219A1 HK 1208219 A1 HK1208219 A1 HK 1208219A1 HK 15108828 A HK15108828 A HK 15108828A HK 1208219 A1 HK1208219 A1 HK 1208219A1
Authority
HK
Hong Kong
Prior art keywords
benzenesulfonyl
pyrrol
pyrazol
phenyl
amino
Prior art date
Application number
HK15108828.4A
Other languages
English (en)
Inventor
于爾根．沃爾茲
馬丁．費斯
羅爾夫-彼得．胡梅爾
馬蒂亞斯．穆勒
托馬斯．梅艾爾
波恩德．穆勒
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of HK1208219A1 publication Critical patent/HK1208219A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
HK15108828.4A 2008-03-12 2015-09-10 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽 HK1208219A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08004568A EP2100882A1 (en) 2008-03-12 2008-03-12 (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts

Publications (1)

Publication Number Publication Date
HK1208219A1 true HK1208219A1 (zh) 2016-02-26

Family

ID=39322749

Family Applications (3)

Application Number Title Priority Date Filing Date
HK13114246.8A HK1186736A1 (zh) 2008-03-12 2013-12-24 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽
HK15108828.4A HK1208219A1 (zh) 2008-03-12 2015-09-10 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽
HK18115376.2A HK1256310A1 (zh) 2008-03-12 2018-11-30 N-磺酰基吡咯衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13114246.8A HK1186736A1 (zh) 2008-03-12 2013-12-24 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18115376.2A HK1256310A1 (zh) 2008-03-12 2018-11-30 N-磺酰基吡咯衍生物

Country Status (16)

Country Link
US (1) US8557858B2 (zh)
EP (2) EP2100882A1 (zh)
JP (2) JP2011513466A (zh)
KR (1) KR101657718B1 (zh)
CN (5) CN104803988A (zh)
AU (1) AU2009224710B2 (zh)
BR (1) BRPI0908917A2 (zh)
CA (1) CA2719071C (zh)
EA (1) EA017533B1 (zh)
HK (3) HK1186736A1 (zh)
IL (1) IL207994A (zh)
MX (1) MX2010010014A (zh)
NZ (1) NZ587823A (zh)
UA (1) UA106351C2 (zh)
WO (1) WO2009112522A1 (zh)
ZA (1) ZA201006523B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4856623B2 (ja) * 2004-03-11 2012-01-18 フォーエスシー アクチエンゲゼルシャフト 新規のｎ−スルホニルピロール誘導体
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
WO2012118782A1 (en) 2011-02-28 2012-09-07 Repligen Corporation Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN102526714B (zh) * 2011-08-24 2013-12-25 贵州神奇集团控股有限公司 治疗肿瘤的药物组合物及其制备方法
CN102716465B (zh) * 2012-06-18 2014-01-15 贵州金桥药业有限公司 治疗肿瘤的药物组合物及其制备方法
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
WO2017060524A1 (en) * 2015-10-09 2017-04-13 4Sc Ag (e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide for the treatment of latent viral infections
MA50070A (fr) * 2017-09-08 2020-07-15 4Sc Ag Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie
KR20200136949A (ko) 2018-03-26 2020-12-08 4에스체 악티엔게젤샤프트 암 치료를 위한 hdac 억제제 및 cd137 작용제를 포함하는 배합물
TW202012395A (zh) * 2018-04-14 2020-04-01 德商４Ｓｃ製藥公司 用於治療癌症的包含組蛋白去乙醯酶（hdac）抑制劑和tlr7 激動劑和/或tlr8 激動劑的藥物組合產品
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
AU2019254578A1 (en) * 2018-04-17 2020-10-22 4Sc Ag Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment
TW202114659A (zh) 2019-10-02 2021-04-16 德商４Ｓｃ製藥公司 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合
CN111973590A (zh) * 2020-07-06 2020-11-24 江苏省人民医院（南京医科大学第一附属医院） 新型hdac抑制剂laq824在治疗弥漫大b细胞淋巴瘤药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
AU5886296A (en) 1995-06-02 1996-12-18 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
JP4856623B2 (ja) * 2004-03-11 2012-01-18 フォーエスシー アクチエンゲゼルシャフト 新規のｎ−スルホニルピロール誘導体
EP1861365B1 (en) 2005-03-15 2009-07-01 4Sc Ag N-sulphonylpyrroles and their use as histone deacetylase inhibitors
WO2006105979A1 (en) * 2005-04-07 2006-10-12 Nycomed Gmbh Sulfonylpyrroles as histone deacetylase inhibitors
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
SI1928872T1 (sl) * 2005-09-21 2012-06-29 4Sc Ag Novi sulfonilpiroli kot inhibitorji HDAC
EP2100878A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors

Also Published As

Publication number Publication date
MX2010010014A (es) 2011-04-05
US8557858B2 (en) 2013-10-15
IL207994A0 (en) 2010-12-30
JP2011513466A (ja) 2011-04-28
EA201001269A1 (ru) 2011-06-30
AU2009224710B2 (en) 2013-05-02
CA2719071C (en) 2016-07-12
CA2719071A1 (en) 2009-09-17
CN101970411A (zh) 2011-02-09
CN103360371A (zh) 2013-10-23
KR20100133422A (ko) 2010-12-21
US20110086897A1 (en) 2011-04-14
UA106351C2 (en) 2014-08-26
IL207994A (en) 2015-10-29
HK1256310A1 (zh) 2019-09-20
HK1186736A1 (zh) 2014-04-17
BRPI0908917A2 (pt) 2021-04-13
WO2009112522A1 (en) 2009-09-17
EP2262775A1 (en) 2010-12-22
NZ587823A (en) 2012-05-25
CN103360371B (zh) 2015-03-25
ZA201006523B (en) 2011-09-28
CN108101890A (zh) 2018-06-01
CN110183425A (zh) 2019-08-30
EP2100882A1 (en) 2009-09-16
EA017533B1 (ru) 2013-01-30
JP2014132027A (ja) 2014-07-17
CN104803988A (zh) 2015-07-29
JP5952328B2 (ja) 2016-07-13
KR101657718B1 (ko) 2016-09-19
AU2009224710A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
HK1208219A1 (zh) -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽
IL209980A0 (en) Sulfonamide compounds or salts thereof
IL205742A0 (en) 4-(4-cyano-2-thioaryl)
AU322949S (en) Vibrator
GB0811643D0 (en) New therapeutic agents
GB2476842B (en) Forceps
GB0808711D0 (en) Tissue assessment
BRPI0822849A2 (pt) Aparelho para cirurgia oftalmológica
EP2349266A4 (en) Sulphonamide-containing compounds and their uses
IL208519A0 (en) Substituted sulfonamide derivatives
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares
ZA201006548B (en) Pyrimidylmethyl sulfonamide compounds
AP2612A (en) Improved herbicidal formulation
GB0702287D0 (en) Tissue tensiometer
GB0821478D0 (en) Novel skin brightening agents
GB0901480D0 (en) Contrast agents
GB0821135D0 (en) Lanthanide compounds
GB0820674D0 (en) Benzamide compounds
ES1068841Y (es) Armario para terminales de usuario
AU4585P (en) WES05 Westringia fruticosa
GB0800265D0 (en) Tissue monitor
ES1068189Y (es) Cabezal para mochos de fregona
GB0722374D0 (en) Benzamide compounds
GB0815765D0 (en) New therapeutic agents
GB0813220D0 (en) Dual aspect dissecting forceps